Theta-burst stimulation for late-life depression works, but slowly

Design

Triple-blind, sham-controlled randomised clinical trial

Population

108 adults aged 60 and over with moderate to severe major depression, not on antidepressants

Primary outcome

Change in Hamilton Depression Rating Scale score

Effect

Week 6 not significant; week 12 mean difference -1.89 (95% CI -3.75 to -0.03), response 52% vs 33%

Options for older adults with depression who are not on antidepressants are limited, and this triple-blind, sham-controlled trial tested bilateral theta-burst stimulation (TBS) in 108 patients aged 60 and over with moderate to severe major depression. Treatment ran daily on weekdays for four weeks, with booster sessions at weeks 6, 8 and 12.

Timing mattered. At week 6 there was no significant difference from sham in Hamilton depression score (mean difference -1.65, 95% CI -3.38 to 0.08). By week 12 active TBS was significantly better (mean difference -1.89, 95% CI -3.75 to -0.03), with response in 52% versus 33%. The effect is real but modest, and it took three months to declare itself.

For practice this adds a non-drug option for late-life depression, useful where antidepressants are declined or poorly tolerated, provided both clinician and patient expect a slow build rather than a quick lift. Set the follow-up out to twelve weeks before judging whether it has worked.

• Triple-blind, sham-controlled trial of bilateral TBS in 108 adults aged 60 and over with moderate to severe depression.
• No significant benefit over sham at week 6 (mean difference -1.65, 95% CI -3.38 to 0.08).
• Significant benefit by week 12 (mean difference -1.89, 95% CI -3.75 to -0.03), response 52% vs 33%.
• Offer it where antidepressants are declined or not tolerated, setting expectations of a slow response.
• Judge the outcome at about twelve weeks, not earlier.

Why it matters

It gives older adults who avoid or cannot tolerate antidepressants a validated alternative, while correcting the expectation that stimulation works fast.

Don't overread it

The effect size is small and reached significance only at week 12; this is a treatment option, not a replacement for established therapies.

The statistics, in plain English

The week-12 confidence interval only just excludes zero (-3.75 to -0.03), so the benefit is statistically significant but small and imprecise; the week-6 interval crosses zero, meaning no proven effect at that point.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.